The synergistic anti-osteosarcoma activity of Rg3 and doxorubicin was also investigated in vitro and in vivo model of osteosarcoma by regulating mTOR/HIF-1α/VEGF and EMT signaling pathways [69]. The gene discussed is MTOR; the disease is osteosarcoma.